Author Archives for Adeline Chauvigné

Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

8 June 2025

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of... View Article

New member | Substra Foundation

8 June 2025

Substra Foundation is an independent nonprofit organization dedicated to fostering the development of trustworthy data science ecosystems. It promotes, protects... View Article

BHealthCare raises € 1.5 M to finalise development of its robotic blood sampling platform, HEIVA™

8 June 2025

BHealthCare, a MedTech specialising in the development of next-generation robotic solutions to provide more reliable peripheral vascular access, has announced... View Article

The “France Relance” stimulus package: the Healthcare Clusters network proposes three options to guarantee French healthcare sovereignty

8 June 2025

Improve access to equity by launching novel specialised investment funds Support research and innovation by issuing calls for projects with... View Article

A Nanofitins production unit: a project run by Affilogic, winner of the industrial relocation plan

8 June 2025

Affilogic, a company specialising in the discovery and development of Nanofitins® for biotherapeutic applications, is one of the 31 projects... View Article

Atlanpole Biotherapies | Customized services

8 June 2025

Broadly speaking, cluster members are offered customized services that open up a path to European funding aimed at boosting innovation... View Article

Valneva prepares for Potential US IPO

8 June 2025

Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, today announced that it will convene an Extraordinary General Meeting (EGM)... View Article

Hemarina and Brest University Hospital (CHRU de Brest): OxyOp2 clinical trial proceeds successfully in all french transplant centers

8 June 2025

Brest University Hospital and Hemarina, a biotech company based in Brittany, announced today they have successfully  topped the 100 people involved in... View Article

New member | Imagin VR

8 June 2025

Imagin VR is a company specialised in designing immersive, interactive and collaborative Virtual Reality devices, as well as developing VR... View Article

Ose Immunotherapeutics announces a successful capital increase of €18.6M by private placement

8 June 2025

Offering close to 2.5 times oversubscribed versus the initial minimum target OSE IMMUNOTHERAPEUTICS (Euronext – FR0012127173 – OSE or the “Company”), an... View Article